Hudson Institute has a focus on the translation of our research to deliver health benefits to the community.
We have a number of opportunities available for collaboration, investment, and licensing, to enable the development and commercialisation of our research and technologies.
Below are examples of technologies developed by Hudson Institute researchers. Contact us if you are interested in these, or if you have specific area you would like to pursue.
|Exosomes from amniotic epithelial cells for the treatment of disease||Our researchers are developing a unique exosome therapy platform based on amniotic epithelial cells.|
|Novel cancer therapies: blocking the cells that control tumour growth||Researchers at Hudson Institute have identified a mechanism by which cancer cells are able to invade and spread, and are targeting this in the treatment of cancer.|
|Engineering a safer MR antagonist for heart failure||Researchers from Hudson Institute and Monash Institute of Pharmaceutical Sciences are working together to develop cardiac-selective mineralocorticoid receptor antagonists for the treatment of chronic heart failure.|
|Improving survival rates: development of a new diagnostic test for ovarian cancer||Researchers at Hudson Institute are trialling a screening test for the detection of ovarian cancer, in the hope of improving survival rates.|
|Improving IVF outcomes: Assessing endometrial receptivity||Our researchers are developing a simple blood test to predict the likelihood of a successful IVF embryo transfer, so clinicians and patients can make informed decisions about treatment.|
For more information on any of our projects, contact Rob Merriel, Chief Commercialisation Officer.